摘要
目的评估应用不同治疗方案治疗急性早幼粒细胞白血病(APL)的近、远期疗效。方法回顾性分析78例APL患者的诱导缓解及缓解后治疗,并作5年随访分析。结果75例(96．2％)患者获得完全缓解(CR),全反式维甲酸(ATRA)治疗组(49例)和ATRA+化疗治疗组(24例)的CR率分别为95．9％和95．8％,两组间的差异无统计学意义(P>0．05)。75例达CR的患者进入缓解后治疗,应用ATRA+化疗(18例)、单用化疗序贯(48例)及大剂量阿糖胞苷(HDAE),7例)的复发率分别为66．7％、35．4％和85．7％,3组间的差异有统计学意义(P值均<0．05)。75例CR患者的1、3、5年总生存率分别为81．5％、61．8％和49．1％,无病生存期分别为78．2％、59．0％和49．1％。中位生存期为86．7个月(95％CI为66．7～106．8个月)。结论APL,诱导缓解率高,远期随访中缓解后应用化疗序贯的复发率较低。
Objective To appraise the short-term and long-term outcome of different regimens for the treatment of patients with acute promyelocytic leukemia（APL）. Methods The induction remission and treatment after remission of seventy-eight cases of APL, and its five-year follow-up study were summarized retrospectively. Results Seventy-five cases obtained complete remission（CR 96.2 % ）, most of them received treatment with ATRA or AT- RA plus chemotherapy, the CR rates of the two groups were similar. Most of the treatments after remission were carried out by ATRA plus chemotherapy or chemotherapy alone. The relapse rates of the two groups were 66.7 % and 35.4 %, respectively with 1-years, 3-years, 5-years overall survival（OS） rates of 81.5 %, 61.8 % and 49.1% ; and diseasefree survival（DFS） rates of 78.2 %, 59.0% and 49.1%, respectively. The median survival period was 86.7 months（95%CI, 66.7-106.8 months）. Condnsions Complete remission rate of induction treatment with APL is high. Long-term follow-up of the treatment after remission shows that the relapse rate of the chemotherapy is low.
出处
《上海医学》
CAS
CSCD
北大核心
2007年第1期37-39,共3页
Shanghai Medical Journal
